Since RIG-I activation can stimulate the mitochondrial apoptotic pathway in a BH3-only protein NOXA-dependent but p53-independent manner [18], it is reasonable that ppp-RNA may also work well against cancer cells with p53 mutations, including NSCLC [26]. This evidence concerns the gene TP53 and non-small cell lung carcinoma.